|Cancer Stem Cell News 7.16 April 25, 2018|
High-content single-cell imaging analysis and flow cytometric analysis identified a MYCN+ CSC subpopulation in the heterogeneous hepatocellular carcinoma cell cultures and showed that these cells were selectively killed by acyclic retinoid . [Proc Natl Acad Sci USA]
Autophagy-related gene 7 (ATG7) facilitated the transcription of OCT4 via β-catenin which binds to the OCT4 promoter, promoting CSC characteristics in prostate cancer, including self-renewal, tumor initiation and drug resistance. [Clin Cancer Res]
Investigators demonstrated that KG1a, a stem-like acute myeloid leukemia (AML) cell line that is resistant to double negative T cells (DNTs) and chemotherapy, and chemotherapy-resistant primary AML samples both became more susceptible to DNT-mediated cytotoxicity in vitro following pre-treatment with daunorubicin. [J Exp Clin Cancer Res]
Scientists showed that TLR4 is a key factor to promote NFκB activation in differentiating glioblastoma stem-like cells (GSCs). TLR4 was upregulated during differentiation of GSCs and promoted transcriptional activation of NFκB as determined by luciferase-reporter assays and expression of NFκB target genes. [Sci Rep]
The authors observed tumor formation in transcriptional coactivator with the PDZ-binding motif (TAZ) transgenic mice after administration of the carcinogen 7,12-dimethylbenzanthracene and demonstrated that tumorigenesis was reliant on the presence of TAZ. [Sci Rep]
Investigators report that the expression of sal-like protein 4 (SALL4), was significantly higher in EGFR mutated lung tumors than in non-tumor tissue. The knockdown of SALL4 expression could suppress spheroid formation and the expression of lung cancer stem cell marker CD44. [Oncogenesis]
Researchers showed that isoharringtonine (IHT) inhibited the proliferation of HCC1806, HCC1937, and MCF-7 cells, and suppressed the migration of HCC1806 and HCC1937 cells in a dose-dependent manner. IHT treatment decreased the proportion of breast CSCs in MCF-7, HCC1806, and HCC1937 cells. [Biomed Pharmacother]
Scientists demonstrated that melatonin potently suppresses the migration and invasion of osteosarcoma cells. Melatonin significantly inhibited the sarcosphere formation of osteosarcoma stem cells and regulated EMT markers of osteosarcoma cells. [Life Sci]
Using a novel, reproducible in vivo xenograft growth assay, the authors determined that tumor-initiating cell frequencies are approximately 1 per 1.5 million unsorted basal cell carcinoma cells. [Methods Mol Biol]
Scientists weigh the arguments supporting the existence of an ‘oncogenic’ ribosome and evaluate its role in cancer evolution. In particular, they provide an analysis and perspective on how the ribosome may play a critical role in the acquisition and maintenance of cancer stem cell phenotype. [Oncogenesis]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
STEMCELL Technologies announced a $45 million joint funding agreement between the Governments of Canada and British Columbia to help the company build a state-of-the-art advanced manufacturing facility. The funding agreement will accelerate the Vancouver company’s rapidly scaling business of providing cutting-edge reagents and tools to support life science researchers around the world working in the cell therapy and regenerative medicine fields. [STEMCELL Technologies Inc.]
Lin BioScience announced that the FDA has granted Orphan Drug Designation to LBS-007 for acute lymphoblastic leukemia. [Lin BioScience Inc.]
Astellas Pharma Inc. announced that it submitted a new drug application for marketing approval of gilteritinib in Japan for the treatment of adult patients with FLT3 mutation-positive (FLT3mut+) relapsed or refractory acute myeloid leukemia. [Astellas Pharma Inc.]
Boston Biomedical, Inc. announced that it has initiated dosing of the first patient in each of two clinical studies evaluating DSP-7888, an investigational cancer peptide vaccine. One study is in combination with checkpoint inhibitors for multiple tumor types, and the other is in combination with bevacizumab in glioblastoma. [Boston Biomedical, Inc.]
The U.K. government said it will endeavor to keep pace with the European Union’s impending changes in clinical trial procedures, bringing some solace to those wondering how the two will stay aligned after Brexit starts in earnest next March. [Questex LLC.]
With less than a year to go before the European Medicines Agency must leave its London headquarters because of Brexit, the agency is facing an unexpected rent increase that could cut into its budget for approving new medicines and overseeing clinical trials. [Nature News]
Young researchers who narrowly miss out on postdoctoral grant struggle to compete with those who just qualify. [Nature News]
NEW 10th International Heinrich F. C. Behr-Symposium on Stem Cells and Cancer
NEW European Society for Medical Oncology (ESMO) 2018 Congress
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.